Agent-Driven Research

Detailed agent analysis

Dive into in-depth weekly reports from our agents, complete with fundamentals, metrics, scoring, key insights and clear investment signals.

Closing prices as of

18 SEP 2026

RDOR3

(Rede D'Or Sao Luiz S.A.)

B3 LISTED

Healthcare • Belo Horizonte, Brazil

R$ 37.23

+12.58%

Reference Price • Change over 90 days

Research Synthesis

Consensus across all agents

NEUTRAL • 78%

The combined picture is of a high-quality business but a less clear-cut stock opportunity at today’s price. Both analysts agree the company itself looks strong: it has stayed profitable over time, appears financially conservative, and operates in a durable area of demand. That gives the investment case a solid foundation and argues against a bearish view. The disagreement is mainly about valuation. One perspective sees the shares as reasonably priced for a business of this quality, while the other sees too little protection if expectations soften or conditions change. That difference matters because when a stock already reflects much of the good news, future returns depend more on continued execution and market confidence than on buying at an obviously favorable price. So the best synthesis is neutral rather than bullish or bearish. The business appears good enough to own on quality, but the entry point does not look compelling enough to make this a strong buy with broad conviction. For existing long-term investors, the case still looks respectable. For new buyers, patience may be warranted unless the company keeps improving enough to justify the valuation or the share price becomes more attractive.

Strength

Business quality is high — durable demand, steady profitability, and a conservative balance sheet support long-term resilience.

Caution

Margin of safety looks limited — if growth or profitability slips, today’s price could leave little room for disappointment.

Watch

Watch whether earnings quality and margins keep improving enough to justify the valuation without relying on market optimism alone.

Agent Conviction Scores

Ben Graham

Deep Value Agent

NEUTRAL • 82%

If I were judging this business in the old-fashioned defensive manner, I would say it is plainly a strong enterprise, but not plainly a strong bargain. That distinction is very important. A good company is not automatically a good investment if the buyer must pay too high a price for it. On the favorable side, the company appears to have the qualities a conservative investor should respect. Its finances seem sound, its obligations do not appear burdensome, and its operations have shown dependable profitability over a number of years. That kind of record is comforting because it suggests the business is built on something real rather than on hope alone. The dividend history adds another reassuring feature, since regular distributions often indicate both earning power and a degree of shareholder consideration. However, the investor must never forget that even an admirable business can become a speculative purchase when the market asks too much for it. Here, the central difficulty is not the company’s character but the price being demanded for participation in that character. Graham’s approach insists on a margin of safety. One does not buy merely because the enterprise is sound; one buys when soundness is available at a sensible discount to reasonable value. Without that protective cushion, the investor is relying too heavily on continued good fortune and favorable market opinion. So the proper conclusion is neither enthusiasm nor condemnation. I would not call this a bearish case, because the business itself seems substantial and well managed. But I also would not call it bullish, because the absence of a sufficient margin of safety deprives the conservative investor of his chief protection against error, disappointment, or changing conditions. In plain terms: this looks like a respectable house offered at too ambitious a price. It may continue to do well, but the careful investor should wait for a more favorable entry rather than stretch his standards. That is why the sound recommendation is neutral.

Inner Scoring Radar

Earnings

Stability 100/100

Growth 50/100

The business shows strong stability, with positive results every year over the past seven years. Growth is present, but it has not followed a steady path, suggesting a generally resilient performance with some uneven momentum.

Financial

Liquidity 100/100

Leverage 100/100

Payout 100/100

The business appears financially strong, with healthy working capital, steady operating profits, and very conservative debt. Balance sheet risk looks low, with little sign of leverage pressure. It has also paid dividends consistently in recent years.

Valuation 25/100

Trading at 2.9x Graham Number — exceeds valuation ceiling, no margin of safety.

Warren Buffett

Value & Moat Agent

BULLISH • 87%

If I were thinking about this business the way I prefer to think about investments, I would start with a simple question: would I be comfortable owning the whole enterprise if the stock market closed for years? In this case, the answer leans clearly yes. This is a business tied to an essential human need. People do not stop requiring hospital care, oncology services, diagnostics, and health coverage because of the mood of the market. That gives the company a degree of staying power that I find attractive. Better yet, it appears to have translated that demand into a business that has been earning good returns while staying financially sensible. That combination usually tells you the operation has some real economic strength rather than just temporary good fortune. The next thing I would look for is consistency. I do not want a business that must reinvent itself every year to survive. This company appears to have a record of expanding steadily, with earnings that generally move in the right direction over time. The fact that profitability can move around somewhat is worth noting, because healthcare businesses can still face cost pressures and integration challenges. But the larger picture suggests a business that is durable, growing, and not dependent on a single lucky period. Management also matters enormously. A good business can be damaged by poor capital allocation, while a very good management team can enhance a strong franchise over time. Here, the signs are encouraging. There appears to be meaningful long-term ownership and a record of treating the business as something to build rather than simply trade around. That does not guarantee perfection, but it does suggest an alignment with owners that I always like to see. Finally, price matters. Even the best business can become a poor investment if bought at too rich a price. In this case, the shares appear to offer at least a reasonable bargain relative to what the business is worth. It may not be the kind of extraordinary discount that makes you pound the table, but it seems fair enough for a company of this quality. And I have long preferred a wonderful company at a fair price to a fair company at a wonderful price. So my conclusion is bullish. Not because the stock is sure to move next week or next quarter, but because the underlying business seems strong, understandable, resilient, and competently run. The main reservation is that the margin of safety does not appear enormous and profitability is not perfectly smooth, so I would be enthusiastic but not reckless. This looks more like the kind of business to own patiently than to speculate on.

Inner Scoring Radar

Fundamentals

ROE 100/100

ROIC 100/100

Leverage 100/100

The business has steadily earned returns above its cost of capital, suggesting it is creating value over time. It has also maintained a cautious level of borrowing relative to equity, staying within a healthy range for its industry.

Consistency

Revenue 100/100

Margin 70/100

Net Income 100/100

The business shows steady revenue growth, pointing to durable demand and ongoing expansion. Profitability remains positive overall, though margins can fluctuate, suggesting some sensitivity to costs or sales mix. Earnings have also risen consistently over time.

Management

Ownership 78/100

Earnings 85/100

Payout 100/100

Ownership appears strong and steady, supported by a long-term insider group holding a meaningful stake. Some outside investors have trimmed positions, but control looks intact. Profitability and dividends have been consistent for 7 years, with growth resilient though uneven.

Valuation 80/100

Moderate margin of safety: market price is below estimated intrinsic value, but the discount is not substantial.

Financial Metrics

Revenue vs Net Income Trend

BRL thousands • 2019-2025

Revenue

Net Income

Balance Sheet Key Components

BRL thousands • 2019-2025

Fixed Assets

Other

Net Debt

Working Capital

Leverage & Efficiency Trends

Debt to Equity 0.2x

Well below healthcare industry average.

Operating Margin 11.0%

Positive operating margin trend, but with significant period-to-period volatility.

Return on Equity 1.4x

Return on equity has consistently exceeded the cost of capital, indicating value creation.

Return on Invested Capital 1.2x

Return on invested capital has consistently exceeded the cost of capital, indicating value creation.

Operating Margin Trend

% • 2019-2025

Ownership Structure & Distributions

Voting Ownership

Shareholder	Voting %
Family Moll	48.2%
Pacific Mezz	12.7%
Free Float	39.1%

Payout History

DIVIDEND

R$ 4.023 / share

Dec 2025

DIVIDEND

R$ 0.357 / share

Dec 2024

DIVIDEND

R$ 0.274 / share

Dec 2023

DIVIDEND

R$ 0.297 / share

Dec 2022